{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:28:05Z","timestamp":1781915285655,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS) is a rare and severe thrombotic microangiopathy caused by genetic or acquired abnormalities leading to activation of the complement alternative pathway on cell surfaces. This process leads to endothelial dysfunction and microvascular thrombosis. The introduction of anti-C5 antibodies has dramatically improved aHUS prognosis; however, these treatments require regular intravenous infusions and block systemic complement activity, exposing the patient to risk of infections. Recently complement inhibitors have been developed to selectively bind injury-associated target molecules, thereby concentrating the drug at specific cellular or tissue sites while preserving systemic complement function. This study evaluated the local complement inhibitory activity of new molecules that exploit the natural localization of C3d at complement activation sites on cells: namely the anti-C3d monoclonal antibody 3d8b conjugated with the first 10 or 17 short consensus repeats (SCRs) of complement receptor 1 (CR1<jats:sub>1\u201310<\/jats:sub> and CR1<jats:sub>1-17<\/jats:sub>, respectively) or the first 5 SCRs of complement factor H (FH<jats:sub>1-5<\/jats:sub>). To this purpose we tested their capability to block C3 deposition and C5b-9 formation on microvascular endothelial cells (HMEC-1) exposed to serum from patients with aHUS. We also assessed their ability to prevent loss of anti-thrombogenic properties in HMEC-1 pre-exposed to aHUS serum and then perfused with control blood. We demonstrate that anti-C3d-antibody conjugated with CR1<jats:sub>1-10<\/jats:sub>, or CR1<jats:sub>1-17<\/jats:sub>, or FH<jats:sub>1\u20135<\/jats:sub> effectively prevented aHUS serum-induced complement activation on HMEC-1, outperforming their non-targeted soluble counterparts. The efficacy of C3 convertase inhibition varied depending on the complement inhibitory component (CR1<jats:sub>1-17<\/jats:sub> &amp;gt; CR1<jats:sub>1-10<\/jats:sub> &amp;gt; FH<jats:sub>1-5<\/jats:sub>). However, all the inhibitors successfully blocked C5 convertase activity and eliminated the pro-thrombogenic effects of aHUS patients\u2019 serum. These findings support the potential of tissue-targeted complement inhibition as a novel, non-systemic therapeutic strategy for aHUS and other diseases characterized by localized complement dysregulation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1620996","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:50Z","timestamp":1750392650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Valeria","family":"Guaschino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Santarsiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gastoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Michael","family":"Holers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelia M.","family":"Violette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Fahnoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Guarinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sistiana","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","article-title":"Genetic atypical hemolytic-uremic syndrome","volume-title":"GeneReviews","author":"Noris","year":"1993"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.06.005","article-title":"Tissue-targeted complement therapeutics","volume":"102","author":"Tomlinson","year":"2018","journal-title":"Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1288597","article-title":"Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway\u2013mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869725","article-title":"Development and optimization of bifunctional fusion proteins to locally modulate complement activation in diseased tissue","volume":"13","author":"Fahnoe","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood>"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005246","article-title":"C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19","volume":"6","author":"Aiello","year":"2022","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.08.014","article-title":"Exuberant endothelial C5b-9 formation in recurrent and de novo posttransplant thrombotic microangiopathy","volume":"9","author":"Aiello","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383123","article-title":"Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity","volume":"15","author":"Tschongov","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/biom13101522","article-title":"The molecular mechanisms of complement receptor 1\u2014It is complicated","volume":"13","author":"Hardy","year":"2023","journal-title":"Biomolecules"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01691","article-title":"Functional characterization of alternative and classical pathway C3\/C5 convertase activity and inhibition using purified models","volume":"9","author":"Zwarthoff","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.211839","article-title":"Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities*","volume":"286","author":"Pechtl","year":"2011","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-609073","article-title":"Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome","volume":"125","author":"Schramm","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13137","article-title":"The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target","volume":"313","author":"Risitano","year":"2023","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.3471.3471","article-title":"Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome","volume":"130","author":"McKinley","year":"2017","journal-title":"Bloodgn>"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:51Z","timestamp":1750392651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1620996"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1620996","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1620996"}}